Comparative Pharmacology
Head-to-head clinical analysis: CORTENEMA versus DEXACEN 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTENEMA versus DEXACEN 4.
CORTENEMA vs DEXACEN-4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, decrease cytokine production, and suppress inflammatory cell migration and activation in the colonic mucosa.
Dexamethasone is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to increased transcription of anti-inflammatory proteins and suppression of pro-inflammatory mediators.
One enema (100 mg hydrocortisone in 60 mL) administered rectally once daily, preferably at bedtime, for 21 days or until clinical response.
Dexamethasone 4 mg orally or intravenously every 6-8 hours; typical adult dose is 4-20 mg/day in divided doses, depending on condition.
None Documented
None Documented
1.8-3.5 hours (plasma); due to rectal administration and low systemic absorption, clinical effects persist longer than plasma levels suggest
3-4 hours; prolonged to 6-8 hours in renal impairment (CrCl <30 mL/min)
Primarily hepatic metabolism with renal excretion of inactive metabolites; <5% unchanged in urine; biliary/fecal elimination of metabolites accounts for ~80%
Renal: 65-80% as unchanged drug; Biliary: 10-15% as metabolites; Fecal: <5%
Category C
Category C
Corticosteroid
Corticosteroid